Navigation Links
Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Date:7/28/2011

> of Sanofi were euro 16,128 million, a decrease of 0.5% on a reported basis. At constant exchange rate, sales increased 1.0%, reflecting the consolidation of Genzyme from April 1st and the impact from U.S. health care reform, EU austerity measures, and the loss of euro 1,347 million of sales due to generic competition. "Other revenues" reached euro 835 million, up 3.5%, positive impact from Plavix® growth in the U.S. (+12.2%) was partially offset by an unfavorable U.S. dollar impact.

Gross profit reached euro 12,013 million, a decrease of 4.9% or 3.0% at constant exchange rates. The ratio of cost of sales was 30.7%, 3.6 percentage points higher, mainly due to the impact of generic competition.

Research and development expenses were euro 2,297 million, up 1.4% or 3.2% at constant exchange rates. Excluding Genzyme, R&D expenses were down 3.5% at constant exchange rates reflecting the benefit from reorganization put in place in the recent years. The ratio of R&D expenses to net sales was 14.2%, 0.2 percentage point higher than in H1 2010.

Selling and general expenses reached euro 4,201 million, up 6.0% or 7.9% at constant exchange rates. Excluding Genzyme, SG&A expenses were up 0.8% at constant exchange rates, reflecting launching costs for Jevtana® in EU, and Allegra® in the U.S. on the OTC market and higher promotional effort on Lantus® in the U.S. as well. The ratio of selling and general expenses to net sales was 26.0%, compared to 24.5% in H1 2010.

Other current operating income net of expenses was an income of euro 23 million versus an income of euro 102 million in H1 2010 which included a euro 87million payments in Q1 2010 received from Teva on sales of Copaxone® in North America (theses payments ceased at the end of Q1 2010). This line also includes a slight foreign exchange gain attributable to the hedging policy, compared to a loss i
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. New Senior Executives Appointed at Sanofi:
2. VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment
3. Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies
4. TPI Ships Macrolide API Samples for International Sales Standard Testing
5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
6. Burlington Medical Supplies Reorganizes Sales and Marketing Operations
7. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
8. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
9. With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing
10. TPI Signs Macrolide API International Sales and Marketing Agreement
11. CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... TAXUS(R) Stent shows no additional very late stent ... 4 ,Boston Scientific Corporation (NYSE: BSX ) ... II clinical trial, demonstrating continued,long-term safety and efficacy ... the TAXUS stent showed no additional stent,thrombosis between ...
... investigators at the,European Society of Cardiology Congress 2007 (ESC ... continued to,provide clinical benefits compared to a bare metal ... follow-up with no differences in safety. At five-year ... the,study continued to be significantly less likely than the ...
Cached Medicine Technology:Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting is ... Italy and is hosted by the Salesian Pontifical University. ... wide variety of topics such as ADHD, anxiety, headaches ... athletes. The scientific program will feature the latest in ... clients to see what is going on in their ...
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3
... Toronto Stock Exchange Symbol: CYT, MONTREAL, Nov. ... global leader in cryotherapy products to treat cardiac,arrhythmias, ... of,CryoCath, will present at both the Piper Jaffray ... on Healthcare Conference. The Piper Jaffray,Conference presentation will ...
... Trigger Milestone Payments Totaling $1 Million to ... ... PCOP ), an innovator in the discovery and development of ... compounds for advancement in its alliance with GlaxoSmithKline (NYSE:,GSK), through its ...
... movie is a,psychological thriller that tells the story of a ... but paralyzed,during heart surgery., It has been 30 years ... ,Coma, is the gripping story of patients,who check into a ... "Five years after the book and movie, I still ...
... of Hematology ... (ASH) Annual Meeting, SEATTLE, Nov. ... announced it intends to utilize the,results of the phase III first-line ... submission to the United States Food,and Drug Administration (FDA) for potential ...
... Today at 10:30 CET, AMSTERDAM, November 27 ... the field of human gene therapy,today announced it ... the,development of AAV-mediated insulin-like growth factor I (IGF-I) ... CET today, the company,s,management will hold a conference ...
... is a close relationship between infection outbreaks on teeth and ... of hair loss which has an unknown origin. Alopecia areata ... on the body. The disease occurs in males and females ... out 1000 people. , Research by professors Jos Antonio Gil ...
Cached Medicine News:Health News:CryoCath to present at Piper Jaffray and BMO Healthcare conferences 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 3Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 4Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 5Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 2Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 4Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 5Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 6Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 2Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 3Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 4Health News:Infection outbreaks on teeth can cause 'alopecia areata' or localized hair loss 2
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
Medicine Products: